泽璟制药：注射用ZG005、注射用ZGGS18与盐酸吉卡昔替尼片联合用于晚期实体瘤的临床试验获得批准

Core Viewpoint - Zai Jing Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of ZG005 and ZGGS18 in combination with Jikaxitinib for advanced solid tumors [2] Group 1: Company Developments - Zai Jing Pharmaceutical announced the approval of clinical trials for ZG005 and ZGGS18, indicating progress in its oncology pipeline [2] - The company's revenue composition for the year 2024 is projected to be 99.73% from pharmaceutical manufacturing and 0.27% from other businesses, highlighting its focus on the pharmaceutical sector [2]